Efficiency and Transparency in Petitions Act

United States116th CongressS-660Senate
Updated: Mar 5, 2019

Summary

Efficiency and Transparency in Petitions Act This bill requires a petition regarding a pending generic drug or biological product application to be submitted to the Food and Drug Administration (FDA) within one year of when the petitioner discovers the issue that is the basis for the petition. The FDA may grant a waiver of the one-year deadline.

Bill texts

Available versions
Introduced (Senate)View official text

1 version available

All available records shown.

Timeline

  1. Introduced in Senate

  2. Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Senate

All available records shown.